Thu, April 14, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Increased Target to $134 on, Apr 14th, 2022

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $130 to $134 on, Apr 14th, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



This is the rating of the analyst that currently disagrees with Raghuram


  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022